http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/ Critiquing the Politics, Policy & Practice of Development Wed, 20 Jan 2010 12:51:47 +0100 http://wordpress.org/?v=2.8.4 hourly 1 http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/comment-page-1/#comment-72406 US Supreme Court Ruling on Patents has International Implications - The Discomfort Zone Sat, 26 May 2007 11:06:15 +0000 http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/#comment-72406 [...] most immediate relation can be seen to Novartis’ challenge of the Indian patent law. Novartis’ Gleevec patent was rejected in India on grounds that the drug was simply a minor [...] [...] most immediate relation can be seen to Novartis’ challenge of the Indian patent law. Novartis’ Gleevec patent was rejected in India on grounds that the drug was simply a minor [...]

]]> http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/comment-page-1/#comment-43912 MSF Starts Petition against Novartis’ Legal Challenge in India - The Discomfort Zone Mon, 22 Jan 2007 15:55:24 +0000 http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/#comment-43912 [...] SciDev.net reports that Médecins Sans Frontières has launched a petition against the court case by Novartis against the Indian government (see previous post for details of the case). Aid organisation Médecins Sans Frontières (Doctors Without Borders) is collecting signatures against a lawsuit filed by pharmaceutical company Novartis. The court case is scheduled for 29 January in Madras. [...] [...] SciDev.net reports that Médecins Sans Frontières has launched a petition against the court case by Novartis against the Indian government (see previous post for details of the case). Aid organisation Médecins Sans Frontières (Doctors Without Borders) is collecting signatures against a lawsuit filed by pharmaceutical company Novartis. The court case is scheduled for 29 January in Madras. [...]

]]> http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/comment-page-1/#comment-43869 Ethical Pharmaceutical Collaboration: A Catch-22 for Patent Law - The Discomfort Zone Sun, 21 Jan 2007 17:47:17 +0000 http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/#comment-43869 [...] Yet, it also presents a catch-22 for both big pharma and proponents of weaker patent legislation. It is best illustrated by Novartis’ challenge to India’s new patent law. Uphold the legality of this new method, and you allow Novartis’ cancer drug Gleevec exclusive marketing rights in India, banning its many generic cousins. Disallow this new method, and you disallow drug development built upon existing molecules. [...] [...] Yet, it also presents a catch-22 for both big pharma and proponents of weaker patent legislation. It is best illustrated by Novartis’ challenge to India’s new patent law. Uphold the legality of this new method, and you allow Novartis’ cancer drug Gleevec exclusive marketing rights in India, banning its many generic cousins. Disallow this new method, and you disallow drug development built upon existing molecules. [...]

]]> http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/comment-page-1/#comment-42083 Indian Pharma: Balancing Patent Rights and Obligations - The Discomfort Zone Sun, 31 Dec 2006 07:00:51 +0000 http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/#comment-42083 [...] An analysis of the Indian Patent Act is particularly timely in view of Novartis’ challenge to the new law. Section 1 of this report sets out, in great detail, the changes made to the Indian Patent Act in 2005, in order to comply with TRIPS requirements. It looks both at commonly understood flexibilities that India has used fully, e.g. pre- and post-grant opposition as well as others that it has not - e.g. compulsory licensing, or the Bolar exceptions. [...] [...] An analysis of the Indian Patent Act is particularly timely in view of Novartis’ challenge to the new law. Section 1 of this report sets out, in great detail, the changes made to the Indian Patent Act in 2005, in order to comply with TRIPS requirements. It looks both at commonly understood flexibilities that India has used fully, e.g. pre- and post-grant opposition as well as others that it has not – e.g. compulsory licensing, or the Bolar exceptions. [...]

]]> http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/comment-page-1/#comment-41465 Dweep Chanana Sat, 23 Dec 2006 04:50:28 +0000 http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/#comment-41465 Hi Vatsan, You are right...I have missed it. A quick Google search shows that will be another emerging front in the IPR wars. Would appreciate any references on the topic, or your posts if any. Hi Vatsan,
You are right…I have missed it. A quick Google search shows that will be another emerging front in the IPR wars. Would appreciate any references on the topic, or your posts if any.

]]> http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/comment-page-1/#comment-41395 vatsan Fri, 22 Dec 2006 15:34:06 +0000 http://www.planetd.org/2006/12/22/novartis-challenges-indian-patent-law/#comment-41395 u seem to have missed the entire data exclusivity debate which is just as bad u seem to have missed the entire data exclusivity debate which is just as bad

]]>